However, both substances lower blood glucose through independent mechanisms, creating a potential additive hypoglycemic effect that increases risk of low blood sugar episodes, particularly in individuals already taking insulin or sulfonylureas
In 2024, Medicare stopped excluding Wegovy from coverage to treat obesity, which occurs along with cardiovascular disease
And then in 2019, I decided to build the company that we just sold, which really came from my awareness in the supplement space, which he had originally asked me and then my business partner, as formulation background, he had been in the biopharma space for over 20 years
Research peptides and investigational compounds Beyond mainstream pharmaceuticals, the research peptide landscape includes several compounds with weight management applications